Empirical antibiotic treatment of nosocomial spontaneous bacterial peritonitis: Should we start direct broader-spectrum antibiotics or not?

Kaynakça (1)

1. Bunchorntavakul C, Chamroonkul N, Chavalitdhamrong D. Bacte- rial infections in cirrhosis: A critical review and practical guidance. World J Hepatol 2016; 8: 307-21. [CrossRef] Fernandez J, Acevedo J, Castro M, et al. Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: a prospective study. Hepatology 2012; 55: 1551-61. [CrossRef] Ariza X, Castellote J, Lora-Tamayo J, et al. Risk factors for resistance to ceftriaxone and its impact on mortality in community, health- care and nosocomial spontaneous bacterial peritonitis. J Hepatol 2012; 56: 825-32. [CrossRef] Jalan R, Fernandez J, Wiest R, et al. Bacterial infections in cirrho- sis: a position statement based on the EASL Special Conference 2013. J Hepatol 2014; 60: 1310-24. [CrossRef] Piano S, Fasolato S, Salinas F, et al. The empirical antibiotic treat- ment of nosocomial spontaneous bacterial peritonitis: results of a randomized, controlled clinical trial. Hepatology 2016; 63: 1299-309. [CrossRef] Ison MG. Empiric Treatment of Nosocomial Spontaneous Bacte- rial Peritonitis: One Size Does Not Fit All. Hepatology 2016; 63: 1083-5. [CrossRef]